Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Consolidated Net Income (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Consolidated Net Income for 10 consecutive years, with -$47.5 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income fell 9.71% to -$47.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$196.6 million through Dec 2025, up 24.57% year-over-year, with the annual reading at -$196.5 million for FY2025, 24.58% up from the prior year.
  • Consolidated Net Income for Q4 2025 was -$47.5 million at Rhythm Pharmaceuticals, up from -$52.9 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $43.8 million in Q1 2021, with the low at -$141.4 million in Q1 2024.
  • Average Consolidated Net Income over 5 years is -$45.0 million, with a median of -$44.5 million recorded in 2022.
  • The sharpest move saw Consolidated Net Income skyrocketed 228.06% in 2021, then crashed 220.07% in 2022.
  • Over 5 years, Consolidated Net Income stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then grew by 2.02% to -$41.6 million in 2023, then decreased by 4.07% to -$43.3 million in 2024, then fell by 9.71% to -$47.5 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$47.5 million, -$52.9 million, and -$46.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.